Compare Genuine Parts Company (GPC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Spyre Therapeutics Inc. Common Stock — how do they compare? Genuine Parts Company trades at $132.25 (market cap $18.15B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Genuine Parts Company is far larger — about 2.5× Spyre Therapeutics Inc. Common Stock's market cap, and Genuine Parts Company pays a 3.23% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GPC | SYRE | |
|---|---|---|
Market Cap | $18.15B | $7.35B |
Volume | 829,167 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $108.92 |
52-Week Low | $92.47 | $22.18 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $24.24B | $6.35B |
Dividend Yield | 3.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $130.71, up 0.84% today, with a bullish technical signal and support near $127. The company reported mixed quarterly earnings, beating in Q1 and Q2 but missing in Q4 2025, while revenue grew to $24.3B in 2025. Net income margin remains thin at 0.13%, and the P/E ratio is elevated at 522.84, indicating high earnings expectations. Recent news highlights the planned spinoff of its industrial unit, Motion, by Q1 2027, which could unlock value.
The outlook is cautiously optimistic, driven by the corporate split catalyst and steady dividend yield, but risks include compressed profitability, high debt levels, and economic sensitivity. Analysts maintain a buy consensus with a $145.75 price target, suggesting 11.5% upside, though execution on the separation and margin improvement are critical for sustained gains.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
